Codexis

Codexis Equity

The The Equity of Codexis (CDXS) as of Sep 27, 2026 is 50.53 M USD. In the previous year, The Equity was 66.93 M USD — a change of -24.50% (lower).

Equity

50.53 MUSD

YoY

-24.50%

Last updated:

In 2026, Codexis's equity was 50.53 M USD, a -24.50% increase from the 66.93 M USD equity in the previous year.

The Codexis Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
56.31 M USD
Jan 1, 2019
105.52 M USD
Jan 1, 2020
170.10 M USD
Jan 1, 2021
164.39 M USD
Jan 1, 2022
144.80 M USD
Jan 1, 2023
86.62 M USD
Jan 1, 2024
66.93 M USD
Jan 1, 2025
50.53 M USD
The Codexis Equity history
YEAREquityYoY
50.53 MUSD-24.50%
66.93 MUSD-22.73%
86.62 MUSD-40.18%
144.80 MUSD-11.92%
164.39 MUSD-3.36%
170.10 MUSD+61.21%
105.52 MUSD+87.40%
56.31 MUSD+129.38%
24.55 MUSD+28.53%
19.10 MUSD-16.52%
22.88 MUSD-13.04%
26.31 MUSD—
Access this data via the Eulerpool API

Codexis Stock analysis

What does Codexis do? Codexis Inc. is an American biotechnology company that specializes in developing innovative biological solutions for a variety of industries. The company was founded in 2002 and is headquartered in Redwood City, California. Business Model: Codexis is service-oriented and provides customized enzyme solutions for companies looking to improve their products through sustainable processes. The company has developed a unique platform called Rational Protein Engineering, which allows for the development of specific enzymes for various industries. Customers benefit from enzyme optimization expertise and know-how. Divisions: Codexis operates in the fields of life sciences, materials science, agrochemicals, and biofuels. 1. Life Sciences: Codexis specializes in the production of enzymes and biocatalysts for the pharmaceutical industry in the life sciences division. The goal is to provide a faster and more efficient manufacturing process for pharmaceutical active ingredients. The company has successfully developed active ingredients for antibodies, lipids, uric acid, and antivirals. 2. Materials Science: In the materials science division, Codexis specializes in the production of enzymes for materials such as dyes, polymers, and cosmetic products. Codexis ensures that these products are efficiently manufactured without the use of environmentally harmful chemicals. 3. Agrochemicals: Codexis offers customized enzyme solutions to agrochemical manufacturers that reduce the use of chemicals and benefit the environment. These enzymes help in the production of pesticides and other agrochemicals. 4. Biofuels: In the biofuels division, Codexis specializes in the production of enzymes for processing corn, harvested plants, or waste products. These enzymes help enable cost-effective biofuel production. Products: Codexis has developed a wide range of products tailored to the needs of various industries. Some of the products recently introduced to the market by Codexis include: 1. CodeEvolver: CodeEvolver is a platform that allows biotechnology companies to quickly create customized enzyme solutions for their specific needs. The process is fully automated and results in a significant reduction in development time and costs. 2. Codex® screening panels: Codexis offers various screening panels that allow customers to quickly and efficiently select the enzymes best suited for their purposes. The panels are suitable for industries including pharmaceuticals, chemicals, and plant protection. 3. Codex® enzymes: Codexis offers a wide range of enzymes specifically designed for different industry needs. This includes enzymes for the production of biofuels, pesticides, cosmetic products, and pharmaceuticals. Overall, Codexis Inc. has demonstrated its ability to deepen the understanding of biocatalysts and introduce innovative biological processes in a variety of industries through its unique Rational Protein Engineering platform. Codexis is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Codexis's Equity

Codexis's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Codexis's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Codexis's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Codexis's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Codexis’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Codexis stock

The Equity of Codexis is 50.53 M USD in 2026.

The Equity of Codexis changed from 66.93 M USD to 50.53 M USD, representing a -24.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Codexis since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Codexis historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Codexis

All Key Metrics — Codexis